Detalles de la búsqueda
1.
Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2.
Nanomedicine
; 21: 102076, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31394261
2.
Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models.
Nanomedicine
; 13(2): 471-482, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27720926
3.
Gulp1 is associated with the pharmacokinetics of PEGylated liposomal doxorubicin (PLD) in inbred mouse strains.
Nanomedicine
; 12(7): 2007-2017, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27288666
4.
Determining the Need for Standardized Infusions and Concentrations at Hospitals within North Carolina.
Hosp Pharm
; 51(3): 237-245, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38745569
5.
Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia.
Blood Adv
; 7(6): 900-908, 2023 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36044391
6.
Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems.
Pharmaceutics
; 13(1)2021 Jan 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33477395
7.
Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective.
Antibodies (Basel)
; 10(3)2021 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34449544
8.
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients.
Antibodies (Basel)
; 8(1)2019 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31544809
9.
Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients.
Cancer Chemother Pharmacol
; 83(1): 61-70, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30327876
10.
Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents.
Methods Mol Biol
; 1831: 201-228, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30051434
11.
Animal models for analysis of immunological responses to nanomaterials: Challenges and considerations.
Adv Drug Deliv Rev
; 136-137: 82-96, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30273617
12.
Factors Affecting the Pharmacology of Antibody-Drug Conjugates.
Antibodies (Basel)
; 7(1)2018 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31544862
13.
Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.
Nanomedicine (Lond)
; 12(16): 2021-2042, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28745129
14.
Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs.
Int J Pharm
; 526(1-2): 443-454, 2017 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-28473237
15.
Challenges in preclinical to clinical translation for anticancer carrier-mediated agents.
Wiley Interdiscip Rev Nanomed Nanobiotechnol
; 8(5): 642-53, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26846457
16.
A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues.
J Pharm Biomed Anal
; 119: 122-9, 2016 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26678179
17.
Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.
Expert Opin Drug Metab Toxicol
; 11(9): 1419-33, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26173794
18.
Ligand binding reveals a role for heme in translationally-controlled tumor protein dimerization.
PLoS One
; 9(11): e112823, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25396429
Resultados
1 -
18
de 18
1
Próxima >
>>